First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.

​ Conditions: Lymphoblastic Lymphoma; Acute Lymphoblastic Leukemia ALL

Interventions: Drug: 4A10

Sponsors: Allterum Therapeutics, Inc; National Cancer Institute (NCI); Cancer Prevention Research Institute of Texas

Not yet recruiting Conditions: Lymphoblastic Lymphoma; Acute Lymphoblastic Leukemia ALL
Interventions: Drug: 4A10
Sponsors: Allterum Therapeutics, Inc; National Cancer Institute (NCI); Cancer Prevention Research Institute of Texas
Not yet recruiting